Agomab wins FDA orphan drug status for idiopathic pulmonary fibrosis asset
Agomab Therapeutics has now secured a US Food and Drug Administration (FDA) orphan drug designation for IPF treatment AGMB-447.
Agomab Therapeutics has now secured a US Food and Drug Administration (FDA) orphan drug designation for IPF treatment AGMB-447.
What's Your Reaction?
